Pfizer (PFE)
(Delayed Data from NYSE)
$28.97 USD
+0.04 (0.14%)
Updated Sep 26, 2024 04:00 PM ET
After-Market: $28.93 -0.04 (-0.14%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$28.97 USD
+0.04 (0.14%)
Updated Sep 26, 2024 04:00 PM ET
After-Market: $28.93 -0.04 (-0.14%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth C Momentum D VGM
Zacks News
Biogen (BIIB) Q3 Earnings: Will it Deliver a Beat Again?
by Zacks Equity Research
At Biogen's (BIIB) Q3 call, investor focus will remain on Tecfidera's scrip trends, pipeline progress and acquisition plans. All eyes will also be on Spinraza's performance in the same quarter.
Eli Lilly (LLY) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance have been performing well. Let's see if these along with its older products lead the company to an earnings beat.
Aerie (AERI) Up on FDA Review Committee Result for Rhopressa
by Zacks Equity Research
Shares of Aerie Pharmaceuticals, Inc. (AERI) have moved up 15.8% in the last week on positive news for its lead drug, Rhopressa.
J&J (JNJ) Beats on Q3 Earnings, Actelion Buyout Drives Sales
by Zacks Equity Research
J&J (JNJ) reported better-than-expected third-quarter 2017 results and raised its 2017 sales and profit outlook.
Zacks Industry Outlook Highlights: Gilead, Teva, Pfizer and Amgen
by Zacks Equity Research
Zacks Industry Outlook Highlights: Gilead, Teva, Pfizer and Amgen
Innovative Pipelines & Regulatory Catalysts to Drive Pharma Stocks
by Arpita Dutt
Innovation, mergers and acquisitions (M&As), strong results, product approvals and positive data flow should act as catalysts for pharma and biotech stocks.
J&J's Psoriasis Drug Stelara Gets FDA Nod for Adolescent Use
by Zacks Equity Research
Johnson & Johnson (JNJ) announced approval of label expansion for its plaque psoriasis drug, Stelara, to include adolescent patients.
Pharma Industry Outlook - October 2017
by Arpita Dutt
New product sales ramping up, R&D success and innovation, strong results, a higher number of FDA approvals and continued strong performance from key products are some of the factors that could contribute to a sustained recovery in the sector.
Spin-Off ETF: Can the Outperformance Continue?
by Sanghamitra Saha
Spin-off activities picked up pace in the United States.
Pharma Stock Roundup: Pfizer Mulls Options for Consumer Healthcare, LLY's Pipeline Setback
by Arpita Dutt
Pfizer (PFE) is looking at strategic options for its Consumer Healthcare business while Merck announced that it won't be seeking approval for its CETP inhibitor.
Merck Will Not Seek Approval for CETP Inhibitor Anacetrapib
by Zacks Equity Research
Merck (MRK) is not seeking approval for its CETP inhibitor anacetrapib, which it had developed for cholesterol management.
Lilly's (LLY) Verzenio Fails in Phase III Lung Cancer Study
by Zacks Equity Research
Lilly's breast cancer drug, Verzenio, failed to achieve primary endpoint in a phase III study evaluating the drug as monotherapy in advanced lung cancer patients.
Pfizer Considering Sale/Spin-Off of Consumer Healthcare Unit
by Zacks Equity Research
Pfizer (PFE) is exploring strategic alternatives for its Consumer Healthcare segment including a partial or a full separation through a spin-off, sale or other transaction.
Stock Market News For Oct 11, 2017
by Zacks Equity Research
The Dow notched up another record close on Tuesday, following a surge in shares of Wal-Mart.
5 Pharma & Biotech Stocks That Could Be Big Winners in Q3 Earnings
by Arpita Dutt
Here is a look at 5 pharma and biotech stocks including Pfizer (PFE) that are expected to post a positive earnings surprise in Q3.
AstraZeneca's Tagrisso Gets Breakthrough Therapy Designation
by Zacks Equity Research
AstraZeneca (AZN) obtained Breakthrough Therapy Designation (BTD) for Tagrisso (osimertinib) for the 1st-line treatment of patients with metastatic epidermal growth factor receptor mutation-positive non-small cell lung cancer.
Forget Teva (TEVA), Buy These 5 Drug Stocks Instead
by Arpita Dutt
With another challenge cropping up for Teva (TEVA) in the form of earlier-than-expected generic competition for the 40 mg dose of Copaxone, here is a look at 5 drug stocks that look better-positioned.
4 Large-Cap Drug Stocks to Buy on Solid Momentum Ahead of Q3
by Zacks Equity Research
The Large Cap Pharmaceuticals industry has gained 20.7% year to date, outpacing 14.7% gain for the S&P 500.
Allergan's Botox Gets FDA Nod for Forehead Line Treatment
by Zacks Equity Research
Allergan (AGN) secures an FDA approval for Botox Cosmetic product for its third indication of forehead line development.
The Zacks Analyst Blog Highlights: Pfizer, AT&T, BlackRock U.S. Bancorp and Walt Disney
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, AT&T, BlackRock U.S. Bancorp and Walt Disney
Quality Dividend ETFs for Turbulent Times
by Zacks Equity Research
Consider these 3 dividend ETFs for your portfolio to fight rising market uncertainty.
Agilent Boosts Market Share With FDA Nod to New Cancer Test
by Zacks Equity Research
Agilent Technologies' (A) recent FDA approval for a cancer diagnostic, PD-L1 IHC 28-8 pharmDx for UC and SCCHN patients will further expand its share in the growing cancer-diagnostic market.
Pharma Stock Roundup: J&J Drug Gets CRL, Label Expansion for Merck and BMY Drugs
by Arpita Dutt
Industry heavyweights like Johnson & Johnson (JNJ), Merck and Bristol-Myers were in the news related to regulatory updates.
Merck's Keytruda Gets FDA Nod for Advanced Gastric Cancer
by Zacks Equity Research
Merck's (MRK) Keytruda received FDA approval for advanced gastric cancer, making it the tenth new indication approved for Keytruda.
Pfizer-Merck KGaA Skin Cancer Drug Bavencio Gets EU Approval
by Zacks Equity Research
Pfizer and German partner Merck KGaA's Bavencio secures an EU approval for metastatic Merkel cell carcinoma. The company also expects to make the drug commercially available within a month.